Medication info
Olmephos H Tablet 5/20/12.5 mg (Amlodipine Besylate, Olmesartan Medoxomil, Hydrochlorothiazide)

Olmephos H Tablet 5/20/12.5 mg (Amlodipine Besylate, Olmesartan Medoxomil, Hydrochlorothiazide)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corporation
Appearance
White-orange round film-coated tablets
Packaging
28 tablets (14 tablets/PTP x 2) / carton
Approval status
Active

MFDS item code 201805226 · Approved 2018.12.21 · Insurance code 644914610

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy of amlodipine and olmesartan
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The amounts of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (65 years or older) Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into account. Blood pressure should be monitored closely and more frequently in older adults. As experience with this medicine in older adults, particularly those aged 75 years or older, is very limited, patients should be monitored very carefully when receiving this medicine.
Child dose
Pediatric patients under 18 years of age: Safety and efficacy have not been established; use of this medicine is not recommended.

Ingredients

Manufacturer
JW Pharmaceutical Corporation

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy of amlodipine and olmesartan

  • Essential hypertension
View approved original text

This medication helps effectively control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled even with combined therapy of Amlodipine and Olmesartan Medoxomil.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The amounts of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (65 years or older) Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into account. Blood pressure should be monitored closely and more frequently in older adults. As experience with this medicine in older adults, particularly those aged 75 years or older, is very limited, patients should be monitored very carefully when receiving this medicine.

Child dose

Pediatric patients under 18 years of age: Safety and efficacy have not been established; use of this medicine is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to any component of this drug, those with certain cardiac, renal, or liver diseases, as well as pregnant or breastfeeding women, and patients with severe hypotension should not take this drug. Patients with low blood volume or low sodium may experience hypotension at the start of treatment with this drug; therefore, sufficient status checks before taking this medication and careful observation afterwards are necessary. This medication can affect kidney function, thus patients with impaired renal function should frequently check their kidney function through blood tests. Patients with poor liver function or liver disease should be cautious, as hepatic coma may occur with this drug, and it is not recommended for patients with severe hepatic impairment. As this medication lowers blood pressure, it may cause orthostatic hypotension or dizziness, so caution is advised while driving or operating hazardous machinery. Patients taking this medication may experience electrolyte imbalances, so it is important to regularly check electrolyte levels through blood tests. The Hydrochlorothiazide component can cause photosensitivity reactions; therefore, exposure to sunlight or ultraviolet light should be avoided, and if any unusual reactions occur, the medication should be discontinued immediately. This medication may interact with other antihypertensive medications or certain drugs, so if you are taking other medications, be sure to inform your doctor or pharmacist. Overdose can lead to severe hypotension or arrhythmia, and if symptoms occur, immediate medical attention should be sought. This medication is not recommended for use in children, and elderly patients should start with a lower dose considering possible renal and liver function decline. During breastfeeding, the ingredients of this medication may pass into breast milk, so breastfeeding women should discontinue breastfeeding or consult a physician when taking this drug. This medication should be stored in a moisture- and heat-free environment and kept out of reach of children. Do not transfer to other containers.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disturbances, dizziness, orthostatic dizziness, syncope, dysgeusia, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, fainting, convulsions, loss of appetite, tremor, vision abnormalities, decreased tear production, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, bloating, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, eruptive pustulosis, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, angioedema, rash, relapse of skin lupus erythematosus, toxic epidermal necrolysis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle cramps, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, frequency of urination, acute kidney failure, hematuria, dysuria, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, increased serum creatinine, elevated blood urea, increased serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, increased liver enzymes, elevated serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, lymphedema, asthenia, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome, choroidal exudate.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and must be stored in a tightly sealed container. The storage temperature should maintain between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White-orange round film-coated tablets

Package unit

28 tablets (14 tablets/PTP x 2) / carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.